Comprehensive Cancer Organisation the Netherlands, Department of Research, Utrecht, The Netherlands.
Comprehensive Cancer Organisation the Netherlands, Department of Research, Utrecht, The Netherlands.
Eur J Cancer. 2018 Sep;101:77-86. doi: 10.1016/j.ejca.2018.06.032. Epub 2018 Jul 20.
BACKGROUND/AIM: Unknown primary tumour (UPT) is the term applied to metastatic cancer, the origin of which remains unidentified. Since cancer treatment is primarily based on the tumour site of origin, treatment of UPT patients is challenging. The number of reports on incidence, treatment and survival of UPT is limited. We hereby report data on patients (2000-2012) with UPT in the Netherlands.
The age-standardised rate (ASR) of 'other and unspecified' malignancies in the Netherlands was compared with other European countries. Patients diagnosed with UPT between 2000 and 2012 were selected from the Netherlands Cancer Registry (NCR) to calculate incidence rates. Patient characteristics, treatment and survival rates were assessed.
The ASR of 'other and unspecified' malignancies in the Netherlands did not differ from the European average ASRs (2008-2012). A total of 29,784 patients with an unknown primary tumour were selected from the NCR (2000-2012). The incidence decreased from 14 per 100,000 person years (European standardised rate) in 2000 to 7.0 in 2012. The most common metastatic sites were liver, lymph nodes, bone and lung (42%, 22%, 16% and 14%, respectively), and approximately two-thirds of patients were diagnosed with metastases at a single site. One-third of the patients were treated; these were mainly younger patients. The overall median survival for all patients was 1.7 months. The median survival of untreated patients was 1.0 month and of treated patients 6.3 months.
The incidence of UPT between 2000 and 2012 is decreasing in the Netherlands, and one-third of these patients received treatment. Survival after diagnosis is limited to months rather than years.
背景/目的：未知原发性肿瘤（UPT）是指转移性癌症，其来源仍未确定。由于癌症治疗主要基于肿瘤的起源部位，因此治疗 UPT 患者具有挑战性。关于 UPT 的发病率、治疗和生存率的报告数量有限。在此，我们报告了荷兰 2000 年至 2012 年 UPT 患者的数据。
将荷兰“其他和未指定”恶性肿瘤的年龄标准化率（ASR）与其他欧洲国家进行比较。从荷兰癌症登记处（NCR）中选择 2000 年至 2012 年间诊断为 UPT 的患者，以计算发病率。评估患者的特征、治疗和生存率。
荷兰“其他和未指定”恶性肿瘤的 ASR 与欧洲平均 ASR（2008-2012 年）没有差异。从 NCR 中（2000-2012 年）共选择了 29784 例患有未知原发性肿瘤的患者。发病率从 2000 年的每 100000 人年 14 例（欧洲标准化率）下降到 2012 年的 7.0 例。最常见的转移部位是肝脏、淋巴结、骨骼和肺部（分别为 42%、22%、16%和 14%），约三分之二的患者被诊断为单一部位转移。三分之一的患者接受了治疗；这些患者主要是年轻患者。所有患者的总体中位生存期为 1.7 个月。未经治疗患者的中位生存期为 1.0 个月，治疗患者的中位生存期为 6.3 个月。
2000 年至 2012 年间，荷兰 UPT 的发病率正在下降，其中三分之一的患者接受了治疗。诊断后的生存时间有限，以月而不是年计算。
